This study demonstrated the potential use of the new NLRP3 inflammatory body inhibitor DAPA in the treatment of T2DM-related MAFLD, especially its role and mechanism in reducing liver lipid deposition and inflammation, protecting and restoring liver cell function. The gene discussed is NLRP3; the disease is type 2 diabetes mellitus.